On the other hand, a systematic review by Silvestri et al. (2021) [10], which aimed at evaluating the incidence and clinical spectrum of cutaneous adverse events in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors, included 41 articles. Here, CDK4 is linked to breast carcinoma.